Earnings ·
Alnylam Pharmaceuticals reported second quarter 2026 financial results on July 30, 2026, achieving total revenues of…
ALNYAlnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals reported second quarter 2026 financial results on July 30, 2026, achieving total revenues of $1.29 billion and GAAP net income of $164 million (GAAP EPS: $1.21). Total net product revenues grew 74% year-over-year to $1.17 billion, driven primarily by a 106% increase in AMVUTTRA sales to $1.01 billion and an 11% rise in Rare disease products to $142 million. The company lowered its full-year 2026 total TTR net product revenue guidance range from $4.4–$4.7 billion to $4.2–$4.5 billion, citing normalized second-line demand growth in the U.S. ATTR-CM market after initial pent-up demand was satisfied. Additionally, Alnylam initiated Phase 2 trials for ALN-6400 and mivelsiran, appointed Benjamin Franklin Cravatt III to its Board, and entered an exclusive commercial agreement with BeOne Medicines for AMVUTTRA in China. The company operates as a biopharmaceutical firm pioneering RNA interference (RNAi) therapeutics.